NCT01188499View on ClinicalTrials.gov

Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

March 31, 2014

Conditions
Cancer
Interventions
DRUG

Birinapant

Trial Locations (7)

14263

Roswell Park Cancer Institute, Buffalo

19104

University of Pennsylvania Abramson Cancer Center, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

33308

Holy Cross Hospital, Fort Lauderdale

48201

Barbara Ann Karmanos Cancer Center, Detroit

75201

Mary Crowley Cancer Research Center, Dallas

78229

South Texas Accelerated Research Therapeutics (START), San Antonio

Sponsors
All Listed Sponsors
lead

TetraLogic Pharmaceuticals

INDUSTRY

NCT01188499 - Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter | Biotech Hunter